Trial of Ateronon in Patients With Coronary Disease to Evaluate Its Effectiveness in Assessing the Risk Factors of Atherosclerosis

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.

Also called NCT01287182

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 100 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01287182
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Lebanon (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01287182. Non-randomized; no masking; primary purpose treatment. Start 2011-05 (registry gives no type); primary completion 2011-12 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Trial of Ateronon in Patients With Coronary Disease to Evaluate Its Effectiveness in Assessing the Risk Factors of Atherosclerosis
Condition
Atherosclerosis
Intervention (Drug)
Ateronon
Lead sponsor
Omicron Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct01287182
Content hash
33b98899c0ba41a183a223ec7687647baad7983f432d0a30d1b8c8115d36ade5